Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion
- PMID: 12684310
- DOI: 10.1378/chest.123.4.1188
Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion
Abstract
Objective: To evaluate the effect of repeated thoracenteses on the fluid characteristics and the levels of various cytokines, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-5, IL-6, and IL-8, and of plasminogen activator inhibitor type 1 (PAI-1) and tissue type plasminogen activator in malignant pleural effusion and its clinical significance.
Design: A prospective study.
Patients and methods: Twenty-six patients with symptomatic and a large amount of free-flow malignant pleural effusions were studied. Thoracentesis with drainage of 500 mL of pleural fluid per day was performed for 3 continuous days (days 1 to 3). The effusion samples were collected to evaluate the changes of fluid characteristics, cytokine levels, and fibrinolytic activity. Chest ultrasonography was done on day 6 to observe the presence of fibrin strands. The result of pleurodesis was evaluated in the patients classified into groups based on chest ultrasonographic findings.
Results: The values of TNF-alpha, PAI-1, IL-8, and neutrophil count in pleural fluid increased significantly during repeated thoracenteses in 26 patients studied. A positive correlation was found between the concentrations of TNF-alpha and PAI-1 and between the values of IL-8 and neutrophils. On day 6, fibrin strands were observed in the pleural effusion on chest ultrasonography in 11 patients (42%, fibrinous group) but were absent in the remaining 15 patients (nonfibrinous group). During repeated thoracenteses, a significant increase of effusion PAI-1 and TNF-alpha was observed in the fibrinous group but not in the nonfibrinous group. In addition, the levels of effusion PAI-1 and TNF-alpha obtained from day 2 and day 3 were significantly higher in the fibrinous group than in the nonfibrinous group. The success rate of pleurodesis was significantly higher in the fibrinous group (11 of 11 patients, 100%) than in the nonfibrinous group (8 of 12 patients, 67%).
Conclusions: Repeated thoracenteses may cause pleural inflammation and induce local release of proinflammatory cytokine as TNF-alpha, which may subsequently enhance the release of PAI-1 and lead to fibrin formation in malignant effusion. The presence of fibrin strands after repeated thoracenteses may be of considerable value in predicting the success of subsequent pleurodesis in patients with malignant pleural effusions.
Comment in
-
Effect of repeated thoracenteses on fibrinolytic activity in malignant pleural effusion.Chest. 2004 May;125(5):1965-6; author reply 1966. doi: 10.1378/chest.125.5.1965. Chest. 2004. PMID: 15136421 No abstract available.
Similar articles
-
Repeated thoracenteses affect proinflammatory cytokines, vascular endothelial growth factor, and fibrinolytic activity in pleural transudates.Am J Med Sci. 2007 Dec;334(6):452-7. doi: 10.1097/MAJ.0b013e318123eead. Am J Med Sci. 2007. PMID: 18091367
-
Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.Chest. 1999 Nov;116(5):1292-6. doi: 10.1378/chest.116.5.1292. Chest. 1999. PMID: 10559090
-
Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.Chest. 2005 Aug;128(2):690-7. doi: 10.1378/chest.128.2.690. Chest. 2005. PMID: 16100155
-
Comparing approaches to the management of malignant pleural effusions.Expert Rev Respir Med. 2017 Apr;11(4):273-284. doi: 10.1080/17476348.2017.1300532. Epub 2017 Mar 8. Expert Rev Respir Med. 2017. PMID: 28271728 Review.
-
Update on Novel Targeted Therapy for Pleural Organization and Fibrosis.Int J Mol Sci. 2022 Jan 29;23(3):1587. doi: 10.3390/ijms23031587. Int J Mol Sci. 2022. PMID: 35163509 Free PMC article. Review.
Cited by
-
Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.BMC Cancer. 2016 Jul 13;16:463. doi: 10.1186/s12885-016-2529-1. BMC Cancer. 2016. PMID: 27411914 Free PMC article.
-
Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.Oncol Lett. 2017 Sep;14(3):3657-3662. doi: 10.3892/ol.2017.6631. Epub 2017 Jul 20. Oncol Lett. 2017. PMID: 28927127 Free PMC article.
-
The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review.Int J Mol Sci. 2021 Feb 1;22(3):1437. doi: 10.3390/ijms22031437. Int J Mol Sci. 2021. PMID: 33535429 Free PMC article. Review.
-
Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.Mol Ther. 2012 Jun;20(6):1139-47. doi: 10.1038/mt.2012.4. Epub 2012 Feb 14. Mol Ther. 2012. PMID: 22334023 Free PMC article.
-
Does pleural fluid appearance really matter? The relationship between fluid appearance and cytology, cell counts, and chemical laboratory measurements in pleural effusions of patients with cancer.J Cardiothorac Surg. 2010 Aug 18;5:63. doi: 10.1186/1749-8090-5-63. J Cardiothorac Surg. 2010. PMID: 20718978 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous